Selank Spray: Why This Is the Strongest Case for Non-Injectable Delivery in the Catalog

Selank is one of the few peptides in this catalog where the nasal spray route has meaningful published research behind it, not just community data. That makes this guide a different conversation than the BPC-157 or TB-500 spray guides.

This guide covers the spray delivery format. For the full compound overview of Selank's mechanisms, anxiolytic research, and cognitive effects, read the Selank compound guide first.

What it is

Selank Spray delivers the heptapeptide Selank (TKPRPGP) through intranasal administration. Selank was originally developed by the Institute of Molecular Genetics of the Russian Academy of Sciences, and the Russian research program studied both injectable and intranasal routes. The nasal route is actually how Selank has been used in its clinical research history.

How delivery format affects research outcomes

Selank is a short 7-amino-acid peptide. Smaller peptides generally have better prospects for nasal absorption than larger ones. More importantly, the nasal route offers a specific advantage for compounds targeting the central nervous system. The olfactory pathway provides access to the brain that bypasses the blood-brain barrier, which is directly relevant for a compound studied primarily for anxiolytic and cognitive effects.

For a CNS-targeted peptide, the argument for nasal delivery is stronger than it is for compounds primarily studied for peripheral tissue repair.

What the research shows on spray formats

Russian clinical research on Selank used intranasal administration as a primary delivery route. Studies showing anxiolytic effects, cognitive enhancement in anxiety models, and modulation of BDNF levels used intranasal protocols. This is meaningfully different from the spray format situation for BPC-157 or TB-500, where almost all the data comes from injectable studies.

The intranasal Selank research showed effects consistent with GABAergic modulation and serotonin system influence, which aligns with the mechanism documented in the broader Selank literature.

Dosing ranges from the literature

Russian clinical protocols for intranasal Selank have used concentrations of 0.15% solution, with doses in the range of 250 to 500 mcg per administration, typically administered two to three times daily. These numbers come from the Russian clinical trial program where intranasal was the primary route studied.

Safety profile

Selank demonstrated a favorable safety profile in the Russian clinical research program using intranasal administration. No significant adverse effects were documented. Nasal mucosal tolerance was acceptable in the study populations. Selank is not a controlled substance and is not on the WADA Prohibited List as of 2026.

DISCLAIMER: The information contained in this post is intended strictly for educational and research purposes. The compounds discussed are research chemicals, not approved drugs or dietary supplements, and are not intended for human consumption. This content does not constitute medical advice, diagnosis, or treatment. No claims are made regarding the safety or efficacy of any compound for use in humans. All dosing ranges referenced are drawn from published scientific literature and are provided for informational context only. Any references to "the rat" are a recognized convention in the research community used to discuss observed responses in a third-party, non-human research context. Do not use any research chemical without the guidance of a licensed healthcare provider who is familiar with your full medical history. Live Alpha Labs products are sold exclusively for laboratory and research use. By engaging with this content, you acknowledge that you are a qualified researcher or informed adult acting in a research capacity.

Discussion questions

1. Selank is unusual among the peptides in this catalog because the clinical research program used intranasal as a primary delivery route rather than injectable. What does this suggest about how researchers should weight intranasal Selank data compared to compounds where spray is a secondary, less-studied format?
2. The olfactory pathway to the CNS is a mechanistically distinct route from systemic injection reaching the brain through circulation. For researchers studying anxiolytic or cognitive endpoints specifically, what differences in onset, duration, or effect profile would you predict between routes based on the pharmacokinetic literature?
3. The Russian Selank research program produced the bulk of the published literature. What are the methodological considerations for evaluating that research in the context of Western clinical trial standards?